Related Experiment Video
Updated: May 31, 2026
08:40
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
Myelin glycosphingolipid immunoreactivity and CSF levels in multiple sclerosis
S Haghighi1, A Lekman, S Nilsson
1Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Sweden.
Acta Neurologica Scandinavica
|June 29, 2011
Summary
Multiple sclerosis (MS) patients show elevated sulfatide levels in cerebrospinal fluid and increased serum IgM antibodies against sulfatide and galactosylceramide (GalCer). Cerebrospinal fluid IgG antibodies against GalCer were detected in some MS patients.
Area of Science:
- Neuroimmunology
- Biochemistry
- Immunology
Background:
- Patients with multiple sclerosis (MS) exhibit antibodies against myelin components, including glycosphingolipids like sulfatide and galactosylceramide (GalCer).
- Previous studies reported inconsistent findings regarding glycosphingolipid levels and antibody profiles in MS patients.
Purpose of the Study:
- To investigate and clarify the levels of sulfatide and antibodies against glycosphingolipids in the cerebrospinal fluid (CSF) and serum of MS patients.
- To explore the relationship between these antibodies and the clinical course of MS.
Main Methods:
- Quantification of sulfatide levels in CSF.
- Measurement of serum and CSF IgM and IgG antibody titers against sulfatide and GalCer.
- Comparison of these levels and titers between MS patients and healthy controls.
Main Results:
- CSF sulfatide levels were significantly increased in MS patients compared to controls (P < 0.001).
- MS patients showed higher serum IgM antibody titers against sulfatide (P = 0.03) and GalCer (P < 0.001) than controls.
- CSF IgG antibodies against GalCer were detected in 7 out of 46 MS patients, but not in controls (P = 0.004).
Conclusions:
- Elevated CSF sulfatide and serum IgM antibodies suggest a role for these molecules in MS, potentially related to early antigen challenge or natural autoimmunity.
- The presence of CSF IgG anti-GalCer antibodies may indicate specific B-cell activation within the central nervous system.
- Serum IgM antibody findings were not correlated with MS disease course or severity, suggesting they are not secondary to myelin damage.
